[Certolizumab Pegol targets inflammatory processes].
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D017326:Clinical Trials, Phase III as Topic; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology / Q000451:nursing*; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D007279:Injections, Subcutaneous; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol